Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
|
|
GW PHARMACEUTICALS PLC (GWPH)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 04/28/2021 |
GN
| GW Pharmaceuticals recognised for leadership in prescription cannabis-based medicines with prestigious Queen's Award for Enterprise in Innovation |
| 04/23/2021 |
GN
| GW Pharmaceuticals Shareholders Approve Acquisition by Jazz Pharmaceuticals |
| 04/20/2021 |
GN
| GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures associated with tuberous sclerosis complex |
| 02/26/2021 |
GN
| GW Pharmaceuticals receives positive CHMP opinion for EPIDYOLEX® (cannabidiol) for use as treatment of seizures associated with Tuberous Sclerosis Complex |
| 02/16/2021 |
GN
| GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2020 Financial Results and Operational Progress |
| 02/06/2021 |
GN
| INVESTIGATION ALERT: Halper Sadeh LLP Investigates VIE, HMSY, GWPH, FLIR; Shareholders Are Encouraged to Contact the Firm |
| 02/03/2021 |
GN
| SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of GW Pharmaceuticals plc Buyout |
| 02/03/2021 |
GN
| GW PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of GWPH and Encourages Investors to Contact the Firm |
| 01/05/2021 |
GN
| CORRECTING and REPLACING - GW Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference |
| 01/05/2021 |
GN
| GW Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference |
| 12/07/2020 |
GN
| GW Pharmaceuticals to Present at the 2020 Needham Virtual Epilepsy & Pain – Specialty CNS Therapeutics Conference |
| 12/01/2020 |
GN
| Greenwich Biosciences to Present Data on EPIDIOLEX® (cannabidiol) Oral Solution at the American Epilepsy Society Annual Meeting |
| 11/30/2020 |
GN
| GW Pharmaceuticals to Present at the Evercore ISI 2020 Healthcare Conference |
| 11/13/2020 |
GN
| Greenwich Biosciences to Present Analysis of Three Clinical Studies of Nabiximols for People with Multiple Sclerosis Related Spasticity at the American Academy of Physical Medicine and Rehabilitation (AAPM&R) Annual Assembly |
| 11/09/2020 |
GN
| GW Pharmaceuticals to Present at the Stifel 2020 Virtual Healthcare Conference |
| 11/03/2020 |
GN
| GW Pharmaceuticals plc Reports Third Quarter 2020 Financial Results and Operational Progress |
| 11/03/2020 |
GN
| GW Pharmaceuticals Initiates Pivotal Phase 3 Study of Nabiximols for Multiple Sclerosis-Associated Spasticity |
| 10/22/2020 |
GN
| GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Third Quarter Ending September 30th, 2020 and Host Conference Call on November 3rd, 2020 |
| 10/21/2020 |
GN
| Greenwich Biosciences, Inc., a Subsidiary of GW Pharmaceuticals plc, Launches unspoken symphony, a Breakthrough Innovation Created for the US Epilepsy Community |
| 09/23/2020 |
GN
| GW Pharmaceuticals receives Australian Therapeutic Goods Administration (TGA) approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy |
| 09/10/2020 |
GN
| Greenwich Biosciences to Present Data on Safety and Efficacy of Nabiximols in Persons with Multiple Sclerosis-Associated Spasticity at the Joint ACTRIMS-ECTRIMS Meeting, MSVirtual2020 |
| 09/10/2020 |
GN
| Greenwich Biosciences to Share Results of Cannabis Use Survey Conducted with the North American Research Committee on Multiple Sclerosis (NARCOMS) at Joint ACTRIMS-ECTRIMS Meeting, MSVirtual2020 |
| 09/01/2020 |
GN
| GW Pharmaceuticals to Present at Upcoming Investor Conferences |
| 08/06/2020 |
GN
| GW Pharmaceuticals plc Reports Second Quarter 2020 Financial Results and Operational Progress |
| 06/30/2020 |
GN
| GW Pharmaceuticals Presents Nabiximols U.S. Development and Commercial Strategy |
| 06/23/2020 |
GN
| GW Pharmaceuticals announces that EPIDYOLEX® (cannabidiol) has been reclassified by the UK Home Office as a Schedule 5 drug |
| 06/04/2020 |
GN
| GW Pharmaceuticals to Host Virtual Investor Event on Its Nabiximols U.S. Development Program and Market Opportunity |
| 05/01/2020 |
GN
| GW Pharmaceuticals to Present at the Bank of America Healthcare Conference 2020 |
| 04/21/2020 |
GN
| GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the First Quarter Ending March 31st, 2020 and Host Conference Call on May 11th, 2020 |
| 04/21/2020 |
GN
| Outlook Therapeutics Bolsters Clinical and Commercial Expertise with Two Key Appointments to Board of Directors |
| 04/06/2020 |
GN
| GW Pharmaceuticals plc and Its U.S. Subsidiary Greenwich Biosciences, Inc. Announce That EPIDIOLEX® (cannabidiol) Oral Solution Has Been Descheduled And Is No Longer A Controlled Substance |
| 03/13/2020 |
GN
| GW Pharmaceuticals submits Type II Variation Application to the European Medicines Agency (EMA) to expand the use of EPIDYOLEX®, (cannabidiol) oral solution, for the treatment of seizures associated with Tuberous Sclerosis Complex (TSC) |
| 03/02/2020 |
GN
| JAMA Neurology Publishes Results from Positive Phase 3 Trial of EPIDIOLEX® (cannabidiol) oral solution in Children with Seizures Associated with Dravet Syndrome |
| 03/02/2020 |
GN
| GW Pharmaceuticals regains exclusive commercialisation rights to Sativex® (nabiximols) in the UK from Bayer |
|
|
|